Development

UroGen's mitomycin shows durable response in Phase III ENVISION bladder cancer trial

Three-year durability data from the ZUSDURI ENVISION trial reinforce the clinical profile of mitomycin (Zusduri) as a non-surgical option for recurrent...

Urogen reported three-year durability data from the ZUSDURI ENVISION trial reinforcing the clinical profile of mitomycin (Zusduri) as a non-surgical option for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. As per a press release from the firm, the median duration of response was still unreached at a median follow-up of 35.5 months.

The Phase III ENVISION trial is a single-arm, multinational, multicenter pivotal study that enrolled 240 adults with recurrent LG-IR-NMIBC across 56 sites. Participants received six once-weekly intravesical instillations of Zusduri, administered in an outpatient setting via urinary catheter using UroGen Pharma's (Nasdaq: URGN) proprietary RTGel sustained-release hydrogel technology. A total 79.6% of patients achieved a complete response at three months, the trial's primary endpoint. Among those complete responders, the Kaplan-Meier estimated probability of remaining event-free at 36 months was 64.5% (95% CI, 54.6%–72.8%), and the median duration of response had not been reached. Notably, this durability was observed without maintenance therapy following the initial six-week treatment course.

Serious adverse reactions occurred in 12% of patients, including urinary retention in 0.8% and urethral stenosis in 0.4%. The most common adverse reactions — occurring in 10% or more of patients — included dysuria, electrolyte and laboratory abnormalities, urinary tract infection, and hematuria, with the majority characterized as mild to moderate in severity.

The demand for alternatives to surgery

LG-IR-NMIBC affects approximately 82,000 people in the US each year, with an estimated 59,000 of those cases representing recurrent disease. The median age at diagnosis is 73 years, a demographic that carries elevated surgical risk from comorbidities and cumulative anesthetic exposure.

The current standard of care is transurethral resection of bladder tumor, or TURBT. Because up to 70% of NMIBC patients experience at least one recurrence, many undergo multiple TURBT procedures over their lifetime. The procedural cycle imposes a compounding burden: repeat surgeries, recovery periods, and the attendant risks that accumulate with each intervention, particularly in older patients.

Zusduri's mechanism addresses this directly. Mitomycin is a bioreductive alkylating agent that crosslinks DNA strands, inhibiting replication and inducing apoptosis in tumor cells. Delivered intravesically via RTGel — a hydrogel that remains liquid at room temperature and transitions to a gel at body temperature — the formulation is designed to maximize bladder contact time and sustained drug exposure, a pharmacokinetic advantage over conventional aqueous mitomycin C solutions that are cleared more rapidly.

The AllSci BriefSystematic R&D and deal news. Daily.

Zusduri received US FDA approval in June 2025, becoming the first and only approved therapy with a label specifically written for recurrent LG-IR-NMIBC. That regulatory precision matters commercially: BCG and conventional intravesical mitomycin C, both guideline-supported in this population, carry broader NMIBC labels rather than the defined LG-IR-NMIBC subgroup classification. Neither is positioned as a chemoablative replacement for TURBT in the way Zusduri is.

Conventional intravesical mitomycin C is typically administered as a single perioperative instillation within 24 hours of TURBT to reduce early recurrence — it is a post-surgical adjunct, not a primary treatment. BCG functions as adjuvant immunotherapy following resection, activating a T-cell-mediated granulomatous response to reduce recurrence and progression risk. Zusduri, by contrast, is designed to ablate existing tumors without surgery.

UroGen has not announced a specific next data readout or regulatory milestone in this update. The 36-month ZUSDURI clinical trial results represent a durability follow-up from an already-approved product rather than a preapproval filing package, positioning the data primarily as a commercial and medical affairs asset. Continued follow-up from the ENVISION trial, with the median duration of response still not reached, will determine whether the 64.5% event-free rate at three years holds or improves as the dataset matures.


This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/


Spot something wrong? Report an issue with this article